Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Yune-Jung | - |
dc.contributor.author | Yoo, Seung-Ah | - |
dc.contributor.author | Hwang, Daehee | - |
dc.contributor.author | Cho, Chul-Soo | - |
dc.contributor.author | Kim, Wan-Uk | - |
dc.date.available | 2017-07-11T05:35:10Z | - |
dc.date.created | 2017-04-10 | - |
dc.date.issued | 2016-02 | - |
dc.identifier.issn | 1226-3613 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11750/2729 | - |
dc.description.abstract | To optimize treatment for rheumatoid arthritis (RA), it is ideal to monitor the disease activity on a daily basis because RA activity fluctuates over time. Urine can be collected routinely at home by patients. Recently, we identified four urinary biomarker candidates-gelsolin (GSN), orosomucoid (ORM)1, ORM2 and soluble CD14 (sCD14)-in RA patients through transcriptomic and proteomic studies. Here, we investigated the clinical significance of the aforementioned urinary biomarker candidates in a prospective manner. For the first time, we found that urinary ORM1, ORM2 and sCD14 levels, but not GSN, were elevated in RA patients and had a positive correlation with the status of the disease activity. In particular, urine tests for ORM 1, ORM 2 and sCD14 efficiently represented the presence of high RA activity without the need for measuring blood markers. In a parallel study, a more rapid radiographic progression over 3 years was observed in patients with higher ORM2 levels. Combined measurements of urinary ORM2 and serum C-reactive protein synergistically increased the predictability of the radiographic progression of RA (odds ratio: 46.5). Collectively, our data provide evidence that blood-free, urinary biomarkers are promising surrogates for assessing disease activity and prognosis of RA. We anticipate that our urinary biomarkers will provide novel candidates for patient-driven measurements of RA activity at home and can shift the paradigm from blood to urine testing in the assessment of RA activity and prognosis in hospitals. | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1038/emm.2015.120 | - |
dc.identifier.scopusid | 2-s2.0-84978639970 | - |
dc.identifier.bibliographicCitation | Experimental and Molecular Medicine, v.48, pp.1 - 8 | - |
dc.identifier.kciid | ART002082803 | - |
dc.description.isOpenAccess | TRUE | - |
dc.subject.keywordPlus | C-Reactive Protein | - |
dc.subject.keywordPlus | CARDIOVASCULAR RISK | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE | - |
dc.subject.keywordPlus | MARKERS | - |
dc.subject.keywordPlus | PATIENT | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | Proteomics | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordPlus | Soluble CD14 | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.citation.endPage | 8 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | Experimental and Molecular Medicine | - |
dc.citation.volume | 48 | - |